The Filing Desk

Fennec Pharmaceuticals vs Protagonist Therapeutics

Fennec Pharmaceuticals FENC · Protagonist Therapeutics PTGX · Biotechnology

Protagonist Therapeutics reported revenue of $46 million in fiscal 2025, about the same as Fennec Pharmaceuticals' $45 million in fiscal 2025. Fennec Pharmaceuticals' revenue fell 6.1% in its latest year, and Protagonist Therapeutics' fell 89.4%. Fennec Pharmaceuticals had an operating margin of -14.1%, against -343.6% at Protagonist Therapeutics.

Side by side

Fennec PharmaceuticalsProtagonist Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$45M$46M
Revenue growth−6.1%−89.4%
Revenue growth a year, last 5 years194.9%10.0%
Gross margin——
Operating margin−14.1%−343.6%
Net margin−21.8%−282.8%
Free cash flow—$56M
Free cash flow margin—121.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count4.7%−2.3%
Last close$13.45$124.02
P/E at the last close—26.3×
Insider trades, last 12 monthssold $9.9 millionsold $79.5 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Fennec PharmaceuticalsProtagonist Therapeutics
Operating margin
Percent of revenue
Fennec PharmaceuticalsProtagonist Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Fennec PharmaceuticalsProtagonist Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Fennec Pharmaceuticals and Protagonist Therapeutics pages.